BioSig Technologies, Inc. STEX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$506.66M-9.5% | -$462.78M-1,061% | -$39.87M-52.2% | -$26.2M-169% | -$9.74M+5.7% | ||
| -$98.85M-46.3% | -$67.56M-137% | -$28.55M-6.4% | -$26.85M-119% | -$12.28M+3.1% | ||
| -$103.86M-46.1% | -$71.1M-132% | -$30.65M-11.5% | -$27.48M-121% | -$12.41M+3.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioSig Technologies, Inc.'s revenue?
- BioSig Technologies, Inc. (STEX) generated $40.0K in revenue over the trailing twelve months, up 122.2% year over year.
- Is BioSig Technologies, Inc. profitable?
- BioSig Technologies, Inc. is not currently profitable: it reported a net loss of $506.7M over the trailing twelve months, a -25825.0% net margin.
- What are BioSig Technologies, Inc.'s profit margins?
- Gross margin is 80.1% and operating margin is -32155.0%, with a -25825.0% net margin.
- What is BioSig Technologies, Inc.'s earnings per share?
- BioSig Technologies, Inc.'s diluted EPS over the trailing twelve months is $-9.71.
- Where does BioSig Technologies, Inc.'s income statement data come from?
- Every line is extracted from BioSig Technologies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
